For the third year in a row VirTrial has been recognized in this prestigious competition. The annual peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma highlights companies that have demonstrated innovative solutions, technologies, and services and have the potential to make the greatest impact for biotech and pharma companies.
This year, VirTrial entered the competition with its newly developed, industry-first, ‘virtual site monitoring™’ solution, Virtual Pre-Site. The solution enables pharmaceutical sponsors and CROs to evaluate, qualify, train and routinely monitor research sites for studies without physical travel. By eliminating the need for Clinical Research Associates (CRAs) to travel, Virtual Pre-Site greatly reduces time requirements, slashes associated costs for clinical trials, and enables existing studies to continue and new studies to start amidst the monumental COVID-19 challenges.
Virtual Pre-Site includes delivery of HD live-streaming glasses that enable an on-site Clinical Research Coordinator (CRC) to provide a remote CRA access to all aspects of the site virtually, simply by walking through the site wearing the glasses. Everything in view of the study coordinator streams to the CRA’s computer screen so she/he can verify the site qualifies for the study, is trained appropriately, and is performing the study to protocol standards.
2018 & 2019 Achievements
VirTrial was honored to be recognized as a finalist in 2018 and named as a winner in 2019 for our Virtual Care Management (VCM) platform. VirTrial’s VCM platform is a proven telemedicine solution customized to drive adoption of hybrid decentralized clinical trials (DCTs). By combining best of breed technology, an open API for interoperability with third party platforms, compatibility with digital medical devices, and support for trials that require a combination of in-clinic and virtual visits, the VirTrial VCM platform is the most powerful and flexible solution on the market. It operates on any device (Android, Apple, phone, tablet, computer) and works with any clinical site worldwide enabling sponsors, CROs, and sites to maintain control over their studies and save time and money in getting medications to market faster.
VirTrial’s VCM platform is unique in that it enables pharmaceutical companies to run hybrid DCTs using their preferred clinical site networks and replace some (not all) study visits with virtual visits. VirTrial’s vision is for 25-50% of visits to be conducted virtually because they understand the irreplaceable value of continuing existing patient-physician relationships via in-person visits when needed for specific procedures or to maintain patient comfort.
About Fierce Innovation Awards
The awards program’s applications were reviewed by an exclusive panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD. All applications were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. See full results in the 2020 Innovation Report.